Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000158 | 0.94 | PPARD (0.48) | PPARDTSHRAOX1HIF1AFAAH | |
| SCHEMBL17764807 | 0.92 | PPARD (0.47) | PPARDTSHRAOX1FAAHTRPV1 | |
| SCHEMBL2382808 | 0.86 | PPARD (0.54) | PPARDTSHRAOX1TP53TDP1 | |
| SCHEMBL4451720 | 0.83 | TSHR (0.44) | PPARDTSHRAOX1HIF1AFAAH | |
| SCHEMBL5017294 | 0.81 | PPARD (0.64) | PPARDTSHRTP53TDP1 | |
| SCHEMBL7268189 | 0.81 | PPARD (0.64) | PPARDTSHRTP53TDP1 | |
| SCHEMBL2957697 | 0.81 | PPARD (0.48) | PPARDTSHRAOX1TP53TDP1 | |
| SCHEMBL7268183 | 0.79 | PPARD (0.61) | PPARDTSHRTP53TDP1 | |
| SCHEMBL11514496 | 0.79 | PPARD (0.61) | PPARDTSHRTP53TDP1 | |
| SCHEMBL11323349 | 0.79 | PPARD (0.61) | PPARDTSHRTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362731-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2362731-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010051206-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-7612148-B2 | Hydrogenation catalyst composition and method for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2009-11-03 | — | — | US | disclosed |
| US-20080146733-A1 | Hydrogenation catalyst composition and method for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2008-06-19 | — | — | US | disclosed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PPARD 295/4885TSHR 3412/4885AOX1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.